Ordering of the N-terminus of human MDM2 by small molecule inhibitors.

Restoration of p53 function through the disruption of the MDM2-p53 protein complex is a promising strategy for the treatment of various types of cancer. Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new class of MDM2 inhibitors, the piperidinones. While these compounds bind to the same site as previously reported for small molecule inhibitors, such as the Nutlins, data presented here demonstrate that the piperidinones also engage the N-terminal region (residues 10-16) of human MDM2, in particular, Val14 and Thr16. This portion of MDM2 is unstructured in both the apo form of the protein and in MDM2 complexes with p53 or Nutlin, but adopts a novel β-strand structure when complexed with the piperidinones. The ordering of the N-terminus upon binding of the piperidinones extends the current model of MDM2-p53 interaction and provides a new route to rational design of superior inhibitors.

[1]  L. Kay,et al.  A Gradient-Enhanced HCCH-TOCSY Experiment for Recording Side-Chain 1H and 13C Correlations in H2O Samples of Proteins , 1993 .

[2]  Ad Bax,et al.  Methodological advances in protein NMR , 1993 .

[3]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[4]  V. Hu The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.

[5]  M. Doyle,et al.  Tight binding affinities determined from thermodynamic linkage to protons by titration calorimetry. , 1995, Methods in enzymology.

[6]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[7]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[8]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[9]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[10]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[11]  K. Wüthrich,et al.  Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.

[12]  S F Howard,et al.  Molecular characterization of the hdm2-p53 interaction. , 1997, Journal of molecular biology.

[13]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[14]  J H Lakey,et al.  Heat does not come in different colours: entropy-enthalpy compensation, free energy windows, quantum confinement, pressure perturbation calorimetry, solvation and the multiple causes of heat capacity effects in biomolecular interactions. , 2001, Biophysical chemistry.

[15]  Robert N. Goldberg,et al.  Thermodynamic Quantities for the Ionization Reactions of Buffers , 2002 .

[16]  M. McCoy,et al.  Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Vassilev,et al.  Targeting the p53–MDM2 interaction to treat cancer , 2004, British Journal of Cancer.

[18]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[19]  J. Deschamps,et al.  Structure-based design of potent non-peptide MDM2 inhibitors. , 2005, Journal of the American Chemical Society.

[20]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[21]  A. Hamilton,et al.  Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.

[22]  Paul N Barlow,et al.  Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. , 2005, Journal of molecular biology.

[23]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[24]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[25]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[26]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[27]  Rafael Brüschweiler,et al.  Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. , 2008, Journal of the American Chemical Society.

[28]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[29]  Ernst Schönbrunn,et al.  Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX* , 2009, The Journal of Biological Chemistry.

[30]  Chandra S Verma,et al.  Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies , 2010, Cell cycle.

[31]  Matteo Magnani,et al.  Molecular Interaction Fields and 3D-QSAR Studies of p53-MDM2 Inhibitors Suggest Additional Features of Ligand-Target Interaction , 2010, J. Chem. Inf. Model..

[32]  C. Prives,et al.  The C-terminus of p53 binds the N-terminal domain of MDM2 , 2010, Nature Structural &Molecular Biology.

[33]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[34]  Gareth Davies,et al.  MDM4 binds ligands via a mechanism in which disordered regions become structured , 2010, FEBS letters.

[35]  S. Chi,et al.  Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. , 2011, Journal of the American Chemical Society.

[36]  Alexander Dömling,et al.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. , 2011, Angewandte Chemie.

[37]  Weirong Yuan,et al.  Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined. , 2012, Journal of the American Chemical Society.

[38]  Y. Muto,et al.  Structural insights into the dual-targeting mechanism of Nutlin-3. , 2012, Biochemical and biophysical research communications.

[39]  J. Canon,et al.  Structure-based design of novel inhibitors of the MDM2-p53 interaction. , 2012, Journal of medicinal chemistry.